Nexalin Technology (Nexalin Technology) Cash And Cash Equivalents : $0.55 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Cash And Cash Equivalents?

Nexalin Technology's quarterly cash and cash equivalents increased from Sep. 2023 ($0.36 Mil) to Dec. 2023 ($0.58 Mil) but then stayed the same from Dec. 2023 ($0.58 Mil) to Mar. 2024 ($0.55 Mil).

Nexalin Technology's annual cash and cash equivalents declined from Dec. 2021 ($0.66 Mil) to Dec. 2022 ($0.16 Mil) but then increased from Dec. 2022 ($0.16 Mil) to Dec. 2023 ($0.58 Mil).

Nexalin Technology Cash And Cash Equivalents Historical Data

The historical data trend for Nexalin Technology's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Cash And Cash Equivalents Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

0.08

0.66

0.16

0.58

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial									0.18	0.23	0.36	0.58	0.55

Nexalin Technology Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nexalin Technology (NAS:NXL) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nexalin Technology Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

Executives

Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133